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ABSTRACT:  
 
 
 
The aim was to ascertain any possible linkage between humoral immune responses to 
principal biomarkers (α-synuclein monomers, its toxic oligomers or fibrils, dopamine and 
S100B) and cellular immunity in Parkinson’s disease development. There were elevated 
autoantibody titers to α-synuclein monomers, oligomers plus fibrils in 72%, 56%, and 17% 
of Parkinsonian patients respectively with a 5-year disease duration.  Additionally, there 
were increased titers to dopamine and S100B (96% and 89%) in the 5-year patient group. 
All of these values subsided in 10-year sufferers.  
Furthermore, CD3+, CD4+, CD8+ T-lymphocyte and B-lymphocyte subsets declined in the 
patient cohort during Parkinsonism indicating disease associated reductions in these 
lymphocyte subsets. 
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1. Introduction  
How the immune system protects Parkinson’s disease (PD) sufferers from toxic misfolded 
proteins requires resolution. It has been shown that α-synuclein protein, as a major PD 
biomarker (Lee et al., 2009) may be present not only as monomeric but also oligomeric 
forms in the substantia nigra or as aggregates in Lewy bodies (Yu and Lubchenko, 2009). It 
has also been demonstrated that prefibrillar aggregates of α-synuclein, as well as other 
amyloid protein species, constitute generic toxins in higher organisms including humans 
(Baglioni et al, 2006). Correspondingly, El-Agnaf et al. (2006) reported raised levels of 
oligomeric forms of α-synuclein in PD patient plasma confirming α-synuclein misfolding 
during neurodegeneration in vivo. Furthermore, as an accompaniment to neurodegenerative 
processes, natural autoimmunity may well be perturbed by generation of toxic protein 
species in humans (Orr et al., 2005; Gruden et al., 2007; Roodveldt et al., 2008). Previously 
we found that peripheral immune responses to amyloid structures are a sensitive indicator 
of the early onset of neurodegenerative diseases (Gruden et al 2004; Gruden et al., 2007). 
We have also evaluated autoimmune reactions to insulin amyloidogenic species as an 
endocrine biomarker in PD (Wihelm et al., 2007). Moreover, it is a distinct possibility that 
dopamine (DA) released from degenerating neurons may influence the process of protein 
misfolding in PD (Pham et al., 2000). Immunological consequences associated with 
inflammation and oxidative stress, have been proposed from the etiological pathogenic 
factors involved in the initial degenerative stages of parkinsonism (Czіonkowska et al., 
2002). One of these crucial factors is raised neurotrophin expression and stimulated release 
from cells by activated microglia. As a result, substantially increased concentrations of 
neurotrophins, for instance S100B, concurrently with toxic olgomeric species of α-
synuclein continue to promote apoptosis and subsequent phagocytosis of DA neurons (Yu 
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and Lyubchenko, 2009; Nagatsu et al., 2000; Rothermundt et al., 2003). In connection with 
this, it is a possibility that synchronized autoimmune responses towards elevated DA and 
neutrotrophic factors, in parallel with autoimmune reactions to toxic α-synuclein species, 
may also limit α-synuclein cytotoxicity. Therefore, the aim of this study is to ascertain any 
potential interrelationship between autoimmune responses to selected PD biomarkers and a 
range of other immune system parkinsonian parameters. 
2. Materials and methods 
2.1 Patients 
PD patients (n=32; 20 males and 12 females; 60.8 ± 2.0 years) were recruited from the 
Center of Neurology, RAMS. Patients underwent neurological examination and were 
diagnosed with PD according to disease severity by the UPDRS (Fahn and Elton, 1987). 
Patient scores ranged from 1 to 4, the majority being of grade 2 on the Hoehn and Yahr 
scale (Hoehn and Yahr, 1967). No opportunistic infections were observed either in PD 
patients or age-matched control subjects.   
 Both patient and control demographics are shown in Table 1. Sixteen PD patients 
presented primarily with tremor accompanied by rigidity, fifteen possessed rigidity 
predominantly along with tremor and one individual was diagnosed with akinetic rigid PD 
(Table 2). Patients were treated with dopaminergic-based antiparkinsonian therapy: the L-
DOPA dopamine precursor agents L-Dopa + carbidopa (Sinemet CR®, Nacom®) or L-
Dopa + benserazide (Madopar®), the non-ergot D2/D3
 
agonists Piribedil (Pronoran®) or 
pramipexole (Miropex®). The mean group dose for L-Dopa over 5.2 ± 0.7 treatment years 
was 411.5 ± 134.6 g/patient. 
Following ethical approval subjects gave informed consent for study participation which 
was conducted in accord with the provisions of the World Medical Association Declaration 
of Helsinki (2000).  
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2.2 Protein samples  
S100B and DA were purchased from Sigma, USA, α-synuclein - Millipore, USA. After 1 h 
of coagulation, blood (5ml) was centrifuged (15 minutes, 3,500g, 4oC). The sera were 
aliquoted into Eppendorf tubes, frozen, stored at -80oC, defrosted immediately prior to 
ELISA. 
 
2.3 Production of α-synuclein amyloidogenic species 
-Synuclein (3 mg/ml) was incubated in 10 mM Na2HPO4 at pH 7.4 and 37C with 
continuous agitation (300 rpm) for 7 days to produce oligomers and 14 days for fibrils.  
 
2.4 ELISA of antibodies to α-synuclein monomers, oligomers, fibrils, S100B and DA  
The titers of serum antibodies to α-synuclein  monomers, oligomers and fibrils also protein 
S100b  were determined by ELISA (Rich  et al., 2001) in 96-well polysterol plates (Costar, 
USA) using 6 repetitions per sample. Microtiter wells were coated with the antigens at 
concentrations of 15.0, 20.0, 20.0 and 10.5 µg/ml, respectively, in 50 mM phosphate buffer, 
pH 8.0 (4 °C) overnight. The plates were washed 3 times with phosphate-buffered saline 
(PBS), 0.05% Tween 20, blocked with 1% w/v BSA in PBS, pH 7.5 (Sigma, USA) for 2 h 
(4 °C) and washed with PBS, 0.05% Tween 20. The coated plates were incubated for 16 h 
(6°C) with the samples of PD patient serum using 2-fold serial dilutions in PBS, over the 
dilution range 1:2 up to 1:3000. The plates were then washed 6 times with PBS plus 0.05% 
Tween 20, and serum antibody-antigen interactions were identified during incubation for 2 
hours at 37°C using horseradish peroxidase conjugated with goat antibodies to human 
immunoglobulins (IgG) (Amersham, UK) at a dilution of 1:1000. The plates were 
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subsequently washed 6 times and incubated for 30 min with o-phenylenediamine (Sigma, 
USA) as substrate in the enzyme reaction. Absorbance at 492 nm was measured using the 
plate reader (Flow Lab., USA). The titer of each serum sample was derived from the 
reciprocal of the greatest dilution at which the enzyme-substrate reaction gave an optical 
density value greater than that of the mean optical density of blanks. The values of titers at 
which we observed immunoreactivity to the antigens were represented in relative dilution 
ratio units. 
 
In the ELISA experiments for evaluating DA-antibody titres, conjugated DA-BSA (Gruden 
et al., 2007) was used at a concentration of 20 µg/ml and two modifications of the reaction 
were made, namely a 5% solution of powdered milk was used as the non-specific blocking 
agent; the secondary horseradish peroxidase conjugated with goat antibodies to human IgG 
(Amersham, UK) were plated at a dilution of 1:2000. 
The following ELISA validation experiments were performed: (i) α-synuclein and S100b 
binding to well surfaces were confirmed in the reaction using laboratory-purified (protein 
A-sepharose) antibodies against α-synuclein and S100b, (ii) the specificity of the 
antigen/antibody interaction was established by addition of equal displacing concentrations 
(10-20 µg/ml) of both antigens to three independent patient serum samples prior to coating 
the sera onto the wells and this yielded values corresponding to blank, (iii) Standard 
concentrations of human IgG (Amersham, UK) were used to construct the calibration curve 
and to confirm the reaction of goat antibodies to human IgG.  
Statistical significance was assumed at p < 0.05, for all measurements unless otherwise 
specified.  
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2.4 PD patient lymphocyte subsets as indicators of immune status 
Indicators of immune status in PD patients included the determination of total T- and B-
lymphocyte content by detecting antigens of lymphocyte differentiation (CD3, CD4, CD8, 
CD16, CD20), antigens of activation (CD25, HLA/Dr, CD95) and adhesion molecules 
(CD11b,CD18) with flow cytofluorometric analysis (FACscan, Becton Dickinson, USA). 
Cortisol was detected using ELISA commercial kits (Roche, France).  
 
2.5 Atomic force microscopy (AFM) 
α-Synuclein amyloid species morphology was examined by PICO PLUS atomic force 
microscopy (Agilent, USA) in a non-contact mode using a 100 µm scanner with 
acoustically driven cantilevers employing imaging procedures (Malisauskas et al., 2003). A 
scanner with a 100 µm scan size and cantilevers carrying 10 nm diameter etched silicon 
probes of the TESP model (Veeco, Netherlands) were applied. Scanning was performed at 
a resonance frequency (312-340 kHz), scan rate of 1 Hz and a resolution of 512 x 512 
pixels. For imaging in air, samples were incubated (30 min) on freshly cleaved mica, 
washed with MiliQ water (3 x 100 μl) and dried overnight. The distribution of dimensions 
of amyloid species was measured in AFM cross-sections.  
 
2.6 Thioflavin-T amyloid binding assay 
Formation of amyloid species was assessed using the thioflavin-T dye binding assay 
(LeVine, 1993). Fluorescence measurements were performed on a Jasco FP-6500 
spectrofluorometer (Jasco, Japan). The dye was excited at 440 nm and emission spectra 
recorded (450-550 nm), setting excitation and emission slits at 3 nm.  
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2.7 Statistical analysis 
Comparison between groups was carried out non-parametrically using the Mann–Whitney 
test and by two tailed Student’s t-test for unequal variance.  
 
3. Results 
3.1 Characterization of α-synuclein oligomeric and fibrillar species 
Oligomeric and fibrillar species of α-synuclein were characterized by the thioflavin-T 
binding assay and AFM analysis prior to ELISA. The formation of amyloid oligomers was 
accompanied by a 5 fold increase of thioflavin-T fluorescence (Figure 1D), indicative of 
cross--sheet formation (Krebs et al., 2000). The oligomers were assessed by AFM as 
round-shapes (Figure 1A) with heights 1.2-3.9 nm (Figure 1B) and a maximal population 
centered around 1.8-2 nm corresponding to 20-mers [16]. The mature fibrils were 
characterized by a 10 fold increase in thioflavin-T fluorescence and displayed typical 
fibrillar morphology (≤1 µm) (Figure 1C).   
 
3.2 Autoimmune responses to α-synuclein monomers oligomers, fibrils, DA and S100B  
There was a significant (P<0.05) increase in autoimmune reactivity towards α-synuclein 
monomers. Autoantibody titers to oligomeric α-synuclein species in the 5-year patient sera 
were 4 fold higher than controls whereas sera from 10-year PD patients displayed lower 
autoantibody levels (Figure 2). There was a discernable peak in antibody titers to both 
forms of α-synuclein at the 5-year disease duration and this subsided during disease 
progression up to 10 years. A doubling of titer values to fibrillar α-synuclein was seen in 
less than 20% of patients versus controls and antibody titers to these protein aggregates 
remained generally low throughout (Figure 2). PD patients were screened for serum 
immune responses towards DA (Figure 2), the mean value being 25 fold higher than age 
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matched controls at 5-years and this markedly fell by the 10-year disease phase. The level 
of immune reactivity to S100B, as reflected by antibody levels in the 5-year PD patients, 
was 4.0 fold higher (P<0.01) than controls. Overall, it is clear that all PD patients displayed 
elevated levels of serum autoantibodies to the markers studied and they reached a zenith 5 
years after disease diagnosis. Moreover, there was no correlation between the autoimmune 
reactivity to any of the biomarkers with respect to age (P<0.02) or gender (P<0.1). 
 
3.3 Indicators of immune status in PD patients 
There were no statistically significant differences in the content of T and B lymphocytes in 
the blood sera of PD patients with a 5- and 10-year disease duration, though this does not 
exclude the possibility of divergence in later stages of the disease. In drug-treated PD 
patients there were reduced counts of total CD3+ lymphocytes (< -21%), helper/inducer 
CD4+ T-cells (-23%), and CD20 positive B-lymphocytes (-16%) (Table 3). There were 
also mildly enhanced HLA-DR cell counts (+16%) and elevated counts of CD11b 
(+241%), CD18+ (+44%), CD25+ (+43%) and CD95+ (+296%) lymphocytes. 
Additionally, CD50+ cells were increased by 20% in PD patients.   
3.4 Serum cortisol content in PD patients 
The concentration of cortisol in PD patients was 893.5 ± 86.3 nM/l compared to a value of 
735.0 ± 46.0 nM/l in controls (i.e. +21.5%, P<0.05).  
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4. Discussion 
We simultaneously analyzed the spectrum of autoantibodies generated to native and 
amyloidogenic α-synuclein species, neurotrophic factor S100B and DA as major PD 
biomarkers in patient blood (Graeber, 2009) along with regulatory T- and B-cells. In altered 
conditions in vitro and in vivo, α-synuclein may self assemble forming ordered fibrils 
(Bertoncini et al., 2005) characterized by cross sheet structures similar to Lewy body 
aggregates (Foltynie, 2008). The initial phase of α-synuclein aggregation is thought to 
involve formation of oligomeric species possessing a higher degree of cytotoxicity than 
their mature fibrils (Stefani et al., 2003). The biological role of α-synuclein remains 
somewhat obscure but it may have a regulatory influence on synaptic vesicular pools such 
as DA (Perez and Hastings, 2004). Aggregation of α-synuclein exacerbates oxidative stress 
and cellular damage (Giasson et al., 2000) which might be a primary cause of 
immunological abnormalities in PD. In order to elucidate potential links amongst the above 
mentioned processes, both clinical and non-clinical experimental approaches were adopted. 
Immune response to α-synuclein amyloid species during PD progression have not 
previously been studied relative to the stages of amyloid structure formation. There was a 
substantial increase in autoantibodies to monomeric α-synuclein in 72% of PD patients with 
a 5-year disease duration. Fifty-six percent of patients displayed higher levels of 
autoantibodies to α-synuclein oligomers and only 17% to fibrillar α-synuclein. At the 10-
year disease stage, all autoantibody titers had returned to control levels, indicating that 
there was a rise in autoantibodies up to 5 years and then a decline (Figure 3). In prior 
studies, multi-epitopic autoantibodies to α-synuclein were disclosed in 65% of patients with 
inherited PD (Papachroni et al., 2007).  Moreover, α-synuclein immunization decreased the 
accumulation of aggregated α-synuclein in neurons and synapses associated with reduced 
neurodegeneration in mice (Masliah et al., 2005). S100B was selected as another indicator 
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of PD pathology since it has been associated with neurodegenerative processes (Donato et 
al., 2009). Immunological studies in mice have additionally shown that S100B expression 
is increased in glial cells after neurotoxin treatment which is known to cause parkinsonism 
(Muramatsu et al., 2003).  Thus, assessment of synchronized immuno-reactivity towards 
our studied proteins in PD may be valuable in exposing on-going neurodegenerative 
processes. In 5-year PD patients, S100B autoantibodies were 4 times higher than controls 
but then dropped to control levels by the 10-year disease stage and this biphasic pattern 
reflects the progression of neurodegeneration. Autoantibodies to boosted DA, similar to the 
other autoantibodies investigated, peaked in 5-year disease sufferers and fell during the 
subsequent progression of PD (Figures 2 and 3). Thus, the overall diminution of the 
immunological pattern of autoantibodies to various disease biomarkers confirmed that 
activity of humoral immunity was diminished during later stage disease progression. The 
biphasic profile of idiotypic antibody generation to functionally important disease proteins 
and DA, plus the fact that constituents of the classical or antibody triggered complement 
cascade occur in Lewy bodies (Yamada et al., 1992), substantiate the finding that PD 
pathology engages humoral immunity (Orr et al., 2005). Thus, in the PD brain, there is a 
detectable level of immunoglobulin G which binds to DA neurons in a concentrated 
distribution at neuronal surfaces or on Lewy bodies co-localized with α-synuclein (Orr et 
al., 2005). Moreover, initiation of humoral immunity in early onset PD may also be 
concomitant with inflammation (Hirsch and Hunot, 2009) which plays a fundamental role 
in parkinsonism (Stolp and Dziegielewska, 2009). Increased production of disordered α-
synuclein species is conducive towards activation of the innate immune system generating 
antibodies to the main molecular participants in disease pathology, the levels of which are 
determined by the stage of PD progression. It might be hypothesized from the current 
findings that there is a protective role for idiotypic autoantibodies to toxic oligomeric α-
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synuclein species with the purpose of abolishing toxic effects of aggregates towards 
dopaminergic substantia nigra cells and in other brain regions pertinent to pathology. 
Moreover, elevation of S100B expression in PD relevant brain structures (Rothermundt et 
al., 2003; Fahn and Elton, 1987) and release of DA (Pham et al., 2000), may activate 
microglia to generate pro-inflammatory cytokines and install changes in cellular immunity 
via the antigens expressed by T- lymphocytes. The overall reduction in cell counts for T-
lymphocytes (CD3+), helper-inducer (CD4+), B-lymphocytes (CD20+) and also cells 
expressing HLA-DR antigen signified PD associated decrements in these cellular subsets. 
In contrast, the patients had raised counts for CD11b+, CD18+, CD25+ and CD95+ 
lymphocytes which was characteristic of pro-inflammatory activation of the immune 
system and inflammatory reactions in microglial cells (McGeer and McGeer , 2008). Thus, 
there are two major arms of the immune system, one which functions through antibodies 
produced by plasma or B-cells, and the other which operates via immune cells including 
CD4+ T-cells. It is the cell-mediated arm of the immune system that is depressed in patients 
diagnosed with PD. Accordingly the current data concur with reported aberrations in PD 
peripheral lymphocyte subsets indicating that T lymphocytes, as well as T-helper and T-
suppressor elements are partially decreased relative to the control ratio of СD4/CD8 
lymphocyte subsets (see Stone et al., 2009). A selective loss of CD4+ lymphocytes has also 
been detected in the early stages of multiple sclerosis and Down’s syndrome suggesting a 
common immunological abnormality in such neurological disorders (Fiszer et al., 1994).  
Furthermore, the reduced lymphocyte subsets observed in our study inevitably relates to 
augmented blood cortisol which would weaken the activity of the immune system by 
prevention of T-cell proliferation (Stypuіa et al., 1996). At the asymptomatic stage of PD 
(≤30% of neuronal loss) when oxidative stress initiates formation of α-synuclein 
amyloidogenic species, humoral immunity actively protects dopaminergic neurons from 
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oligomeric toxicity by producing a variety of antibodies to the complex of disease 
biomarkers which includes α-synuclein oligomers themselves. (see Figure 3 at the 5-year 
disease stage). As PD progresses (≥ 50% neuronal loss), diminishing autoantibody binding 
to DA yields a relative lack of antioxidant activity, so autoimmunity fails to cope with 
oxidative stress and cytotoxicity. During the decline in lymphocyte subsets in PD patients 
(Figure 3) free DA influences mitochondrial respiration causing release of cytochrome C 
and in so doing, this initiates neuronal apoptosis (Berman and Hastings, 1999). Similarly, 
overexpression of S100B, along with neurodegenerative processes (Rothermundt et (al., 
2003), blood-brain barrier dysfunction (Stolp and Dziegielewska, 2009) and impaired 
autoantibody protection at the progressive stages of PD may be conducive to DA cell loss. 
In summary, it has become accepted that processes of α-synuclein misfolding and the 
appearance of toxic aggregates may invoke humoral immunity in the pathological gambit 
causing dopaminergic neuronal death in PD. Also, during PD progression, T-cell immunity 
subsides together with microglial activation to become increasingly involved in the cascade 
of neurodegenerative processes. The current findings suggest possible links between α-
synuclein toxicity elimination by autoantibodies to its oligomers in early onset PD 
pathology (Figure 3) and decay of lymphocyte subsets which reflects the influence of 
inflammatory and oxidative stress reactions. Moreover, as PD can be difficult to diagnose 
in the initial stages, determination of the autoantibody profile to disease associated 
biomarkers may be a supplementary diagnostic tactic (Hawa et al., 2004). Hence, humoral 
immunity is directed to protect and prevent the brain from substantial cytotoxicity and 
neurodegeneration and thus, potential PD treatment strategies should attempt to maintain 
patient immune status. 
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Figure 1. AFM imaging and thioflavin-T fluorescence assay of -synuclein amyloid 
species produced in sodium phosphate buffer pH 7.4 at 220C with agitation. (A) AFM 
height image of amyloid oligomers formed after 7 days of incubation; (B) distribution of 
the heights of oligomeric species measured by AFM cross-section analysis; (C) AFM 
height image of amyloid fibrils of -synuclein produced under the same conditions after 14 
days of incubation.  (D) Thioflavin-T fluorescence intensities measured at 480 nm in the 
presence of monomeric -synuclein, amyloid oligomers and fibrils, respectively.   
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Figure 2. Titers of serum antibodies (relative dilution ratios) to -synuclein monomer 
and-synuclein amyloid oligomers in controls (black columns) and Parkinson’s disease 
patients (hatched columns) with ≤5 year disease duration (A), to -synuclein monomer 
and-synuclein amyloid oligomers in controls (black columns) and Parkinson’s disease 
patients (hatched columns) with ≥10 year disease duration (B), dopamine in controls (black 
columns) and Parkinson’s disease patients (hatched columns) with ≤5 year disease duration 
(C) and ≥10 year disease duration (C) and protein S100B in controls (black columns) and 
Parkinson’s disease patients (hatched columns) with ≤5 year disease duration (D) and ≥10 
year disease duration (D), respectively. *p≤0.05, **p≤0.01 
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Figure 3. Schematic showing the differential generation of autoantibodies to-synuclein 
monomers, oligomers, S100B and dopamine in 5- and 10-year Parkinson’s disease sufferers 
in relation to their declining immune status and progressively increasing indicators of 
inflammation and oxidative stress. 
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Table 1. Group characteristics of the study population (group mean ± s.e.m) 
 
 
Group characteristics 
 
 
PD patients (n =32) 
 
Controls (n = 26) 
 
Age (years) 
 
60.8 ± 2.0 
 
63.0 ± 3.0 
 
Gender n (male:female ratio) 
 
 
20:12 
 
19:7 
 
Age at onset of PD (years) 
 
 
60.8 ± 2.0 
 
- 
 
Duration of PD (years) 
 
 
8.6± 3.4 
 
- 
 
aUPDRS motor score 
 
 
23.3 ± 1.9  
 
- 
 
Hoehn and Yahr stage 
 
 
2.1 ± 0.6  
 
- 
aUPDRS: Unified Parkinson’s disease rating scale 
 
 
Table 2.  Clinical analysis of Parkinson disease patients by Unified Parkinson’s 
disease rating scale (UPDRS) 
 
 
Clinical components of UPDRS 
 
 
UPDRS Score 
(mean ± s.e.m) 
 
Impairment of daily activity  
 
 
18.7 ± 1.6 
 
Motor activity  
 
 
23.3 ± 1.9 
 
Tremor  
 
 
2.3 ± 0.13 
 
Rigidity 
 
 
2.2 ± 0.14 
 
                             Bradykinesia 
 
 
2.0 ± 0.18 
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Table 3. Indicators of immune status of PD patients and controls (mean ± s.e.m)  
 
Antigen 
 
Control group 
(lymphocyte 
counts) 
 
PD patients  
 
(lymphocyte 
counts) 
% 
change 
CD3 61.1 ± 0.9 48.3 ± 2.9 a  -21 
CD4 34.3 ± 0.7 26.5 ± 1.8 a  -23 
CD8 30.0 ± 1.5 25.2 ± 1.3      -16 
CD4/CD8 1.2 ± 0.1 1.1 ± 0.1 0 
CD20 5.7 ± 0.8 4.8 ± 0.5 a      -16 
HLA-DR 7.2 ± 0.5 8.4 ± 1.1 a  +16 
CD16 11.4 ± 0.5 16.7 ± 2.3 a 
 
    +46 
CD11b 11.9±0.8 23.0 ± 1.6 a   +241  
CD18 56.8±1.1 81.9 ± 3.2 a  +44 
CD50 69.4 ± 1.1 83.5 ± 4.4 a  +20 
CD95 11.8 ± 0.4 35.0 ± 2.5 a  
 
+296 
CD25 3.1 ± 0.4 5.4 ± 1.1 a  
 
+43 
 
a P<0.05 
 
 
